Cyclic AMP agonist inhibition increases at low levels of histamine release from human basophils.
The relationship between the intensity of the signal for antigen-induced immunoglobulin E-mediated histamine release from human basophils and the concentration of agonist needed to inhibit release has been determined. The agonists, prostaglandin E1, dimaprit, fenoterol, isobutylmethylxanthine and dibutyryl cyclic AMP, all act by increasing the cyclic AMP level. Each agonist was 10- to 1000-fold more potent (relative ID50) at low levels of histamine release (5-10% of total histamine) than at high levels (50-80%). Thus, the inhibitory potential of a drug is a function of the concentration of antigen used to initiate the response. Our results are now more in accord with the inhibitory profile of these drugs in human lung tissue. It is suggested that in vivo release is likely to be low and that this is the level at which to evaluate drugs in vitro.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000328:Adult; D001491:Basophils / Q000187:drug effects* / Q000378:metabolism; D003994:Bucladesine / Q000494:pharmacology; D000242:Cyclic AMP / Q000502:physiology*; D003864:Depression, Chemical; D017259:Dimaprit; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D011458:Prostaglandins E / Q000494:pharmacology; D013890:Thiourea / Q000494:pharmacology
D011458:Prostaglandins E; D003994:Bucladesine; D000242:Cyclic AMP; D013890:Thiourea; D015056:1-Methyl-3-isobutylxanthine; D017259:Dimaprit